Replies to post #138981 on Biotech Values

[pcrutch]

Speak of the devil

Regeneron Announces Data Publication and Presentations

with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
- Phase 1 studies published in March 22, 2012 issue of New England Journal of Medicine
- Phase 2 studies to be presented March 25-26 at American College of Cardiology Annual Meeting

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - News) today announced that results of the Phase 1 clinical program with their investigational product REGN727/SAR236553, a novel, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) were published in the March 22, 2012 issue of the New England Journal of Medicine. The primary author of the article, entitled "Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol," was Evan A. Stein, M.D., Ph.D., Director of the Metabolic and Atherosclerosis Research Center in Cincinnati, Ohio, and Principal Investigator of one of the REGN727/SAR236553 Phase 1 clinical trials.

Additionally, results of two of three completed Phase 2 studies of REGN727/SAR236553 will be presented at oral sessions at the American College of Cardiology (ACC) annual meeting. The presentations are:

"A Randomized, Double-Blind, Placebo-Controlled Trial Of The Safety And Efficacy of a Monoclonal Antibody To Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, REGN727/SAR236553, in Patients With Primary Hypercholesterolemia" will be presented by James M. McKenney, Pharm.D, Professor Emeritus, Virginia Commonwealth
University School of Medicine, during a Late-Breaking Clinical Trial session on Monday, March 26 at 11:14 AM.

"The Effects of Co-administering a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, REGN727/SAR236553, with 10 and 80 mg Atorvastatin Compared to 80 mg Atorvastatin Alone in Patients With Primary Hypercholesterolemia" will be presented by Eli M. Roth, M.D., Professor of Clinical Medicine and Director of Preventive Cardiology for the Division of Cardiology, University of Cincinnati College of Medicine, on Sunday, March 25 at 8:25 AM.